Feb 11 (Reuters) - CSL Ltd (CSL) :
- PRIVIGEN® (IMMUNE GLOBULIN INTRAVENOUS (HUMAN), 10% LIQUID) GRANTED ORPHAN-DRUG DESIGNATION FOR THE INVESTIGATIONAL TREATMENT OF SYSTEMIC SCLEROSIS (SSC)
Feb 11 (Reuters) - CSL Ltd (CSL) : PRIVIGEN® (IMMUNE GLOBULIN...
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$279.90 |
Change
0.340(0.12%) |
Mkt cap ! $135.2B | |||
| Open | High | Low | Value | Volume |
| $279.74 | $281.78 | $278.67 | $138.3M | 494.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 249 | $279.89 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $280.00 | 2440 | 12 |
View Market Depth
| Last trade - 16.10pm 08/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$279.61 |
Change
0.340 ( 0.09 %) |
||||
| Open | High | Low | Volume | ||
| $279.64 | $281.76 | $278.68 | 74293 | ||
| Last updated 15.59pm 08/05/2024 ? | |||||
| CSL (ASX) Chart |